Sugi Predict

Sugi Predict / Compounds / SCHEMBL2061998

SCHEMBL2061998

SCHEMBL2061998

CC(C)(C)OC(=O)NCc1ccccc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 1/20 0.54
▸ HDAC1 Q13547 3/20 0.52
▸ KDM4A O75164 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ RCE1 Q9Y256 1/20 0.49
▸ HDAC10 Q969S8 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ NAMPT P43490 2/20 0.44
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ NQO2 P16083 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CTSS P25774 1/20 0.43
▸ CTSK P43235 1/20 0.43
▸ MALT1 Q9UDY8 1/20 0.42
▸ IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8018113 0.89 KCNA5 (0.56) KCNA5HDAC1KDM4AHDAC10HDAC6
SCHEMBL30159605 0.89 KCNA5 (0.56) KCNA5HDAC1KDM4AHDAC10HDAC6
SCHEMBL13310201 0.88 HPGD (0.47) KCNA5HDAC1KDM4AKDM4EALDH1A1
SCHEMBL27273924 0.87 NQO2 (0.46) KCNA5HDAC1KDM4AKDM4EALDH1A1
SCHEMBL6676878 0.87 KCNA5 (0.46) KCNA5HDAC1KDM4AKDM4EALDH1A1
SCHEMBL31250995 0.85 NQO2 (0.56) KCNA5HPGDNAMPTCA12CA1
SCHEMBL1231492 0.85 NQO2 (0.56) KCNA5HPGDNAMPTCA12CA1
SCHEMBL6924987 0.84 KCNA5 (0.51) KCNA5HDAC1KDM4AHDAC10HDAC6
SCHEMBL4911225 0.84 KCNA5 (0.44) KCNA5HDAC1KDM4AKDM4EALDH1A1
SCHEMBL283455 0.84 KCNA5 (0.44) KCNA5HDAC1KDM4AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss THE ROCKEFELLER UNIVERSITY (US) 2026-05-05 — — US disclosed
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
EP-4551563-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2025-05-14 — — EP disclosed
CN-119816487-A FC conjugates comprising CD73 inhibitors and uses thereof 奇达拉治疗公司 2025-04-11 — — CN disclosed
EP-4100008-B1 PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS UNIV ROCKEFELLER (US) 2025-04-02 — — EP disclosed
WO-2025064869-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER CIDARA THERAPEUTICS, INC. (US) 2025-03-27 — — WO disclosed
WO-2024158698-A1 NOVEL F-ATPASE HYDROLASE INHIBITORS LUCY THERAPEUTICS, INC. (US) 2024-08-02 — — WO disclosed
WO-2024010810-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed
US-20230391730-A1 INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA 2023-12-07 — — US disclosed
US-11814385-B2 Small molecule inhibitors targeting Clostridioides difficile sporulation UNIVERSITY OF SOUTH FLORIDA (US) 2023-11-14 — — US disclosed
EP-0785784-A1 4-HETEROCYCLIC PIPERIDINES PROMOTE RELEASE OF GROWTH HORMONE Merck & Co., Inc. (US) 1997-07-30 — — EP disclosed
EP-0755392-A4 ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1997-05-02 — — EP disclosed
EP-0755392-A1 ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1997-01-29 — — EP disclosed
US-5574044-A BENZIMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF MYOPIA MERCK & CO., INC. (US) 1996-11-12 — — US disclosed
EP-0714299-A4 — — 1996-07-10 — — EP disclosed
EP-0714299-A1 BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1996-06-05 — — EP disclosed
WO-1996013265-A1 4-HETEROCYCLIC PIPERIDINES PROMOTE RELEASE OF GROWTH HORMONE MERCK & CO., INC. (US) 1996-05-09 — — WO disclosed
WO-1996013262-A1 MUSCARINE ANTAGONISTS MERCK & CO., INC. (US) 1996-05-09 — — WO disclosed
WO-1995028397-A1 ALPHA1C ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1995-10-26 — — WO disclosed
WO-1995002405-A1 BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1995-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617785-B2 Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss YAP1, LATS2, LATS1 KCNA5 2821/4885HDAC1 1888/4885KDM4A 2647/4885
US-20230391730-A1 INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS BPTF, BRPF3, PHF6 KCNA5 3244/4885HDAC1 63/4885KDM4A 816/4885
US-11814385-B2 Small molecule inhibitors targeting Clostridioides difficile sporulation SPOUT1, CLPP, RPN2 KCNA5 4014/4885HDAC1 176/4885KDM4A 2767/4885
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF FCGR2A, FCGR1A, FCGR3B KCNA5 2476/4885HDAC1 2417/4885KDM4A 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.